Switch theme
Sign up to access all valuation multiples
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
1991
281
LTM Revenue $209M
LTM EBITDA $7.1M
$263M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cerus has a last 12-month revenue (LTM) of $209M and a last 12-month EBITDA of $7.1M.
In the most recent fiscal year, Cerus achieved revenue of $180M and an EBITDA of -$10.0M.
Cerus expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cerus valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $209M | XXX | $180M | XXX | XXX | XXX |
| Gross Profit | $126M | XXX | $99.5M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | $7.1M | XXX | -$10.0M | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | -6% | XXX | XXX | XXX |
| EBIT | -$13.5M | XXX | -$14.2M | XXX | XXX | XXX |
| EBIT Margin | -6% | XXX | -8% | XXX | XXX | XXX |
| Net Profit | -$20.5M | XXX | -$20.9M | XXX | XXX | XXX |
| Net Margin | -10% | XXX | -12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $63.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Cerus's stock price is $1.
Cerus has current market cap of $245M, and EV of $263M.
See Cerus trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $263M | $245M | XXX | XXX | XXX | XXX | $-0.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Cerus has market cap of $245M and EV of $263M.
Cerus's trades at 1.5x EV/Revenue multiple, and -26.3x EV/EBITDA.
Equity research analysts estimate Cerus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cerus has a P/E ratio of -12.0x.
See valuation multiples for Cerus and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $245M | XXX | $245M | XXX | XXX | XXX |
| EV (current) | $263M | XXX | $263M | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 37.0x | XXX | -26.3x | XXX | XXX | XXX |
| EV/EBIT | -19.5x | XXX | -18.5x | XXX | XXX | XXX |
| EV/Gross Profit | 2.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -12.0x | XXX | -11.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 30.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCerus's last 12 month revenue growth is 11%
Cerus's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.4M for the same period.
Cerus's rule of 40 is -6% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cerus's rule of X is 30% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cerus and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | -6% | XXX | XXX | XXX |
| EBITDA Growth | 66% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -6% | XXX | 5% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 30% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 63% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cerus acquired XXX companies to date.
Last acquisition by Cerus was XXXXXXXX, XXXXX XXXXX XXXXXX . Cerus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cerus founded? | Cerus was founded in 1991. |
| Where is Cerus headquartered? | Cerus is headquartered in United States of America. |
| How many employees does Cerus have? | As of today, Cerus has 281 employees. |
| Who is the CEO of Cerus? | Cerus's CEO is Mr. William M. Greenman. |
| Is Cerus publicy listed? | Yes, Cerus is a public company listed on NAS. |
| What is the stock symbol of Cerus? | Cerus trades under CERS ticker. |
| When did Cerus go public? | Cerus went public in 1997. |
| Who are competitors of Cerus? | Similar companies to Cerus include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Cerus? | Cerus's current market cap is $245M |
| What is the current revenue of Cerus? | Cerus's last 12 months revenue is $209M. |
| What is the current revenue growth of Cerus? | Cerus revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Cerus? | Current revenue multiple of Cerus is 1.3x. |
| Is Cerus profitable? | Yes, Cerus is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cerus? | Cerus's last 12 months EBITDA is $7.1M. |
| What is Cerus's EBITDA margin? | Cerus's last 12 months EBITDA margin is 3%. |
| What is the current EV/EBITDA multiple of Cerus? | Current EBITDA multiple of Cerus is 37.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
